Senolytic therapy in mild Alzheimer’s disease shows safety in phase I trial

Researchers conducted the phase 1 trial of orally-administered senolytic therapy comprising quercetin (Q) and dasatinib (D) for symptomatic and early-stage Alzheimer’s disease (AD) patients.

Is DOAC a Viable Option After Bioprosthetic Valve Surgery Even in Sinus Rhythm?

CHICAGO — Edoxaban (Savaysa) appeared at least on par with warfarin for 12-week thromboembolic prophylaxis after bioprosthetic valve surgical implant in a Japanese trial with

November 18, 2024

Tennis Players at U.S. Open Say Their Mental and Physical Health Are Ignored

It’s nothing new for tennis players to worry aloud about their sport’s overcrowded calendar, too-tough season, and too-short offseason. No. 1-ranked Iga Swiatek added an

August 30, 2024

Gilead’s chief medical officer to leave as R&D efforts stall

Gilead Sciences’ chief medical officer will leave the company early next year as the drugmaker struggles to find new areas of growth beyond its core

July 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.